ArticleOncogene2005
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Identification and subsequent validation of transcriptomic signature associated with metabolic status in endometrial cancer.Scientific reports · 2023Article
- Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.Cancers · 2023Review
- PPARγ regulates the expression of genes involved in the DNA damage response in an inflamed endometrium.Scientific reports · 2022Article
- A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy.Journal of oncology · 2022Article
- Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration-resistant prostate cancer.Molecular oncology · 2021Article
- Review
- Cyclin A1 is associated with poor prognosis in oesophageal squamous cell carcinoma.Oncology letters · 2019Article
- Targeting Angiogenesis in Prostate Cancer.International journal of molecular sciences · 2019Review
- Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.Trends in cancer · 2018Review
- The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.Molecular medicine (Cambridge, Mass.) · 2018Article
- CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells.Oncology reports · 2018Article
- Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.European journal of cancer (Oxford, England : 1990) · 2016Article
- Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis.Scientific reports · 2016Article
- DCE MRI of prostate cancer.Abdominal radiology (New York) · 2016Review
- Cyclin A1 regulates the interactions between mouse haematopoietic stem and progenitor cells and their niches.Cell cycle (Georgetown, Tex.) · 2015Article
- Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.Cancer research · 2013Article
- Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.Oncogene · 2013Article
- Article
- The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer.Cell cycle (Georgetown, Tex.) · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated levels of cyclin A1 expression have been implicated in acute myeloid leukemia and in male germ cell tumors. However, a role of cyclin A1 in tumorigenesis of prostate cancer has not been reported. In the present study, expression of cyclin A1 in patients with prostate cancer and a role of cyclin A1 in mediating expression of vascular endothelial growth factor (VEGF) were investigated. Cyclin A1 was highly expressed in aggressive tumors and was significantly correlated with VEGF expression in 96 patients with prostate cancer. Treatment of LNCaP cells with R1881, a synthetic androgen resulted in increased cyclin A1 expression. Induction of cyclin A1 expression in LNCaP cells led to an increase in VEGF expression and this effect was manifested upon the R1881 treatment. Cyclin A1 failed to mediate VEGF activation in DU-145 cells lacking a functional Rb and an androgen receptor (AR). Although AR expression was induced into DU-145 cells, cyclin A1 was unable to mediate VEGF expression. However, induced coexpression of cyclin A1, Rb and AR in DU-145 cells in the presence of R1881 greatly promoted VEGF promoter activity. This suggests that cyclin A1 mediates VEGF expression in cooperation with Rb- and androgen-dependent pathways in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.